In Vitro Diagnostics Market Scope And Analysis

Report Code : TIPBT00002657
Category : Life Sciences

Status : Published
No. of Pages : 210

Buy Now

In-Vitro Diagnostic Market Scope and Analysis by 2030

Buy Now

In-Vitro Diagnostic Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 72.39 Billion
Market Size by 2030	US$ 112.1 Billion
Global CAGR (2022 - 2030)	5.6%
Historical Data	2020-2021
Forecast period	2023-2030
Segments Covered	By Product & Service Reagents & Kits Instruments Software & Services By Technology Immunoassay/ Immunochemistry Clinical Chemistry Molecular Diagnostics Microbiology Blood Glucose Self-Monitoring Coagulation and Hemostasis Hematology Urinalysis By Application Infectious Diseases Diabetes Oncology Cardiology Autoimmune Diseases Nephrology By End User Hospitals Laboratories Home Care
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Abbott Laboratories F Hoffmann La Roche Ltd Danaher Corp Siemens AG Sysmex Corp Thermo Fisher Scientific Inc Becton Dickinson and Co bioMerieux SA Bio Rad Laboratories Inc

Competitive Landscape and Key Companies:

A few of the prominent in-vitro diagnostic manufacturers operating in the global in-vitro diagnostic market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Danaher Corp, Siemens AG, Sysmex Corp, Thermo Fisher Scientific Inc, Becton Dickinson and Co, bioMerieux SA, Bio-Rad Laboratories Inc, Qiagen NV. These companies focus on new technologies, advancements in existing products, and geographic expansions to meet the increasing consumer demand worldwide and growing their product range in specialty portfolios. For instance, in October 2020, Abbott signed a non-exclusive royalty-bearing license agreement with Quanterix Corporation. Under the agreement, Abbott has gained access to Quanterix’s portfolio of bead-based technology patents for in vitro diagnostic (IVD) applications. In addition, Quanterix received an initial license fee, regulatory and launch milestones, milestone fees subject to achievements associated with Abbott’s future developments, and royalties on the sale of licensed products.